TouchONCOLOGY got the chance to catch up with Rocio Garcia-Carbonero (Hospital Universitario 12 de Octubre, Madrid, Spain) on the use of octreotide acetate with axitinib for the treatment of patients with non-pancreatic neuroendocrine tumors (Clinical Trial Identifier: NCT01744249). The abstract ‘A phase II/III randomized double-blind study of octreotide acetate with axitinib versus octreotide acetate with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).’ (ABSTRACT NUMBER: 360) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- What is the rationale for the combination of octreotide with axitinib in the treatment of patients with non-pancreatic neuroendocrine tumors (NETs)? (0:20)
- Could you tell us a little about the AXINET trial-GETNE-1107 and its findings? (2:09)
- Since the combination of axitinib and octreotide failed to demonstrate a significant improvement in PFS compared with placebo and octreotide, what will be the next steps in the investigation of axitinib for non-pancreatic NETs? (6:04)
Disclosures: RGC has provided scientific advice and/or received honoraria or funding for continuous medical education from AAA, Advanz Pharma, Bayer, HMP, Ipsen, Merck, Midatech Pharma, MSD, Novartis, PharmaMar, Pfizer, Pierre Fabre, Roche, Servier and Sanofi, and has received research support from Pfizer, BMS and MSD.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Oncology
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Jean-Luc Van Laethem, ASCO GI 2021: Pembrolizumab for Advanced Hepatocellular Carcinoma
We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) around pembrolizumab therapy in patients with previously untreated advanced hepatocellular carcinoma (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!